Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
With
NanoMab Technology (UK) Limited
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Participant is willing and able to give informed consent for the participation in the study before any protocol-specific screening procedures are performed
Male or female, aged 18-75 years old
Previous diagnosis of non-small cell carcinoma, confirmed with pathology tests
AST, ALT, BUN, Cr not more than double the normal values
Patients with no current history of hepatitis A, hepatitis B, AIDS, tuberculosis and other infectious diseases
You may not be if
Severe infection
Unable to provide biopsy sample for testing PD-L1 expression level
Patients with pacemakers
Pregnant and lactating women
Investigators professional decision that the subject should not participate in this clinical study
Clareo Health | 99mTc/68Ga Labeled Anti-PD-L1 sdAb in Assessment of PD-L1 Expression in NSCLC
